ACADIA Pharmaceuticals Inc (ACAD)

26.02
0.25 0.95
NASDAQ : Health Care
Prev Close 26.27
Open 26.28
Day Low/High 25.86 / 26.69
52 Wk Low/High 16.64 / 50.40
Volume 1.15M
Avg Volume 1.61M
Exchange NASDAQ
Shares Outstanding 122.05M
Market Cap 3.34B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference On May 16, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce First Quarter 2017 Financial Results On May 9, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Doug Kass shares his thoughts on Twitter, Apple and Alphabet.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At Needham & Company's 16th Annual Healthcare Conference On April 5, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The Cowen And Company 37th Annual Health Care Conference On March 6, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

Allergan, Apple, Facebook: Doug Kass' Views

Allergan, Apple, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on buying retail, and discusses why he's favoring the short side in a big way.

Allergan, Citigroup, Apple: Doug Kass' Views

Allergan, Citigroup, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how he had one of his best days in recent memory, and warns you not to look in the rear view mirror.